These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 22754764)

  • 21. THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells.
    Sun C; Shou P; Du H; Hirabayashi K; Chen Y; Herring LE; Ahn S; Xu Y; Suzuki K; Li G; Tsahouridis O; Su L; Savoldo B; Dotti G
    Cancer Cell; 2020 Feb; 37(2):216-225.e6. PubMed ID: 32004441
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aberrant Lck Signal via CD28 Costimulation Augments Antigen-Specific Functionality and Tumor Control by Redirected T Cells with PD-1 Blockade in Humanized Mice.
    Gulati P; Rühl J; Kannan A; Pircher M; Schuberth P; Nytko KJ; Pruschy M; Sulser S; Haefner M; Jensen S; Soltermann A; Jungraithmayr W; Eisenring M; Winder T; Samaras P; Tabor A; Stenger R; Stupp R; Weder W; Renner C; Münz C; Petrausch U
    Clin Cancer Res; 2018 Aug; 24(16):3981-3993. PubMed ID: 29748183
    [No Abstract]   [Full Text] [Related]  

  • 23. OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity.
    Kitamura N; Murata S; Ueki T; Mekata E; Reilly RT; Jaffee EM; Tani T
    Int J Cancer; 2009 Aug; 125(3):630-8. PubMed ID: 19455675
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor.
    Henderson MA; Yong CS; Duong CP; Davenport AJ; John LB; Devaud C; Neeson P; Westwood JA; Darcy PK; Kershaw MH
    Immunotherapy; 2013 Jun; 5(6):577-90. PubMed ID: 23725282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.
    Gargett T; Brown MP
    Cytotherapy; 2015 Apr; 17(4):487-95. PubMed ID: 25573334
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
    Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
    Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inclusion of Dap10 or 4-1BB costimulation domains in the chPD1 receptor enhances anti-tumor efficacy of T cells in murine models of lymphoma and melanoma.
    Kintz H; Nylen E; Barber A
    Cell Immunol; 2020 May; 351():104069. PubMed ID: 32106933
    [TBL] [Abstract][Full Text] [Related]  

  • 29. OX40 signaling is involved in the autoactivation of CD4
    Jiang J; Liu C; Liu M; Shen Y; Hu X; Wang Q; Wu J; Wu M; Fang Q; Zhang X
    Arthritis Res Ther; 2017 Mar; 19(1):67. PubMed ID: 28320444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.
    Tang XY; Sun Y; Zhang A; Hu GL; Cao W; Wang DH; Zhang B; Chen H
    BMJ Open; 2016 Dec; 6(12):e013904. PubMed ID: 28039295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. OX40 costimulation enhances interleukin-4 (IL-4) expression at priming and promotes the differentiation of naive human CD4(+) T cells into high IL-4-producing effectors.
    Ohshima Y; Yang LP; Uchiyama T; Tanaka Y; Baum P; Sergerie M; Hermann P; Delespesse G
    Blood; 1998 Nov; 92(9):3338-45. PubMed ID: 9787171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.
    Savoldo B; Ramos CA; Liu E; Mims MP; Keating MJ; Carrum G; Kamble RT; Bollard CM; Gee AP; Mei Z; Liu H; Grilley B; Rooney CM; Heslop HE; Brenner MK; Dotti G
    J Clin Invest; 2011 May; 121(5):1822-6. PubMed ID: 21540550
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tuning spacer length improves the functionality of the nanobody-based VEGFR2 CAR T cell.
    Taheri FH; Hassani M; Sharifzadeh Z; Behdani M; Abdoli S; Sayadi M; Bagherzadeh K; Arashkia A; Abolhassani M
    BMC Biotechnol; 2024 Jan; 24(1):1. PubMed ID: 38178096
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evidence implicating the Ras pathway in multiple CD28 costimulatory functions in CD4+ T cells.
    Janardhan SV; Praveen K; Marks R; Gajewski TF
    PLoS One; 2011; 6(9):e24931. PubMed ID: 21949793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.
    Song DG; Ye Q; Poussin M; Harms GM; Figini M; Powell DJ
    Blood; 2012 Jan; 119(3):696-706. PubMed ID: 22117050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD28 and 41BB Costimulatory Domains Alone or in Combination Differentially Influence Cell Surface Dynamics and Organization of Chimeric Antigen Receptors and Early Activation of CAR T Cells.
    Mezősi-Csaplár M; Szöőr Á; Vereb G
    Cancers (Basel); 2023 Jun; 15(12):. PubMed ID: 37370693
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo.
    De Smedt T; Smith J; Baum P; Fanslow W; Butz E; Maliszewski C
    J Immunol; 2002 Jan; 168(2):661-70. PubMed ID: 11777959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
    Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
    Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.
    Long AH; Haso WM; Shern JF; Wanhainen KM; Murgai M; Ingaramo M; Smith JP; Walker AJ; Kohler ME; Venkateshwara VR; Kaplan RN; Patterson GH; Fry TJ; Orentas RJ; Mackall CL
    Nat Med; 2015 Jun; 21(6):581-90. PubMed ID: 25939063
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CD28 ligands CD80 (B7-1) and CD86 (B7-2) induce long-term autocrine growth of CD4+ T cells and induce similar patterns of cytokine secretion in vitro.
    Levine BL; Ueda Y; Craighead N; Huang ML; June CH
    Int Immunol; 1995 Jun; 7(6):891-904. PubMed ID: 7577797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.